公开(公告)号：WO2016145279A3

公开(公告)日：2016-10-27

申请号：PCT/US2016021933

申请日：2016-03-11

Applicant: STC UNM ,  THE OFFICE OF INNOVATION COMMERCIALIZATION ,  HALL PAMELA R ,  DALY SETH MICHAEL ,  OBERLIES NICHOLAS HUNTER ,  RAJA HUZEFA A ,  FIGUEROA-SALDIVAR MARIO A ,  HORSWILL ALEXANDER ROBERT ,  KAVANAUGH JEFFREY SCOTT

Inventor： HALL PAMELA R ,  DALY SETH MICHAEL ,  OBERLIES NICHOLAS HUNTER ,  RAJA HUZEFA A ,  FIGUEROA-SALDIVAR MARIO A ,  HORSWILL ALEXANDER ROBERT ,  KAVANAUGH JEFFREY SCOTT

IPC: A61K31/122 ,  A61K31/7056 ,  A61P3/10 ,  A61P29/00 ,  A61P31/00

CPC classification number: A61K31/122

Abstract: This disclosure describes pharmaceutical compositions and methods that involve the use of a polyhydroxyanthraquinone to inhibit quorum sensing in a microbe. In some embodiments, the polyhydroxyanthraquinone may be effective to antagonize AgrA function in a microbe. In other embodiments, the polyhydroxyanthraquinone may be effective for prophylactic and/or therapeutic treatment of a skin and soft tissue infection (SSTI) of a subject by a microbe. In still other embodiments, the polyhydroxyanthraquinone may be effective to reduce, limit progression, ameliorate, or resolve, to any extent, a symptom or clinical sign of infection by a microbe

Abstract translation: 本公开描述了涉及使用多羟基蒽醌抑制微生物群体感应的药物组合物和方法。 在一些实施方案中，多羟基蒽醌可有效拮抗微生物中的AgrA功能。 在其它实施方案中，多羟基蒽醌可有效用于通过微生物预防和/或治疗受试者的皮肤和软组织感染（SSTI）。 在其它实施方案中，多羟基蒽醌可以有效地减少，限制进行，改善或解决微生物感染的症状或临床症状的任何程度

公开(公告)号：WO2016145279A2

公开(公告)日：2016-09-15

申请号：PCT/US2016/021933

申请日：2016-03-11

Applicant: STC.UNM ,  THE OFFICE OF INNOVATION COMMERCIALIZATION ,  HALL, Pamela, R. ,  DALY, Seth, Michael ,  OBERLIES, Nicholas, Hunter ,  RAJA, Huzefa, A. ,  FIGUEROA-SALDIVAR, Mario, A. ,  HORSWILL, Alexander, Robert ,  KAVANAUGH, Jeffrey, Scott

Inventor： HALL, Pamela, R. ,  DALY, Seth, Michael ,  OBERLIES, Nicholas, Hunter ,  RAJA, Huzefa, A. ,  FIGUEROA-SALDIVAR, Mario, A. ,  HORSWILL, Alexander, Robert ,  KAVANAUGH, Jeffrey, Scott

IPC: A61K31/122 ,  A61K31/7056 ,  A61P31/00 ,  A61P29/00 ,  A61P3/10

CPC classification number: A61K31/122

Abstract: This disclosure describes pharmaceutical compositions and methods that involve the use of a polyhydroxyanthraquinone to inhibit quorum sensing in a microbe. In some embodiments, the polyhydroxyanthraquinone may be effective to antagonize AgrA function in a microbe. In other embodiments, the polyhydroxyanthraquinone may be effective for prophylactic and/or therapeutic treatment of a skin and soft tissue infection (SSTI) of a subject by a microbe. In still other embodiments, the polyhydroxyanthraquinone may be effective to reduce, limit progression, ameliorate, or resolve, to any extent, a symptom or clinical sign of infection by a microbe

Abstract translation: 本公开描述了涉及使用聚羟基蒽醌抑制微生物群体感应的药物组合物和方法。 在一些实施方案中，聚羟基蒽醌可有效拮抗微生物中的AgrA功能。 在其他实施方案中，聚羟基蒽醌可有效预防和/或治疗受试者的微生物的皮肤和软组织感染（SSTI）。 在其他实施方案中，聚羟基蒽醌可有效减少，限制进展，改善或解决任何程度的微生物感染的症状或临床征兆。

公开(公告)号：WO2016137968A3

公开(公告)日：2016-09-01

申请号：PCT/US2016/019092

申请日：2016-02-23

Applicant: STC.UNM ,  MELANCON, Charles ,  HALL, Pamela ,  GREENBERG, Jacob ,  OGASAWARA, Yasushi ,  ROGELJ, Snezna

Inventor： MELANCON, Charles ,  HALL, Pamela ,  GREENBERG, Jacob ,  OGASAWARA, Yasushi ,  ROGELJ, Snezna

IPC: A61K31/03 ,  A61P31/04

Abstract: In one aspect, this disclosure describes a pharmaceutical composition that generally includes frankiamicin A and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method of treating a subject having, or at risk of having, a condition caused by a microbial infection treatable with frankiamicin A. Generally, the method includes administering to the subject an amount of frankiamicin A effective to ameliorate at least one symptom or clinical sign of the condition.

公开(公告)号：WO2016137968A2

公开(公告)日：2016-09-01

申请号：PCT/US2016019092

申请日：2016-02-23

Applicant: STC UNM ,  MELANCON CHARLES ,  HALL PAMELA ,  GREENBERG JACOB ,  OGASAWARA YASUSHI ,  ROGELJ SNEZNA

Inventor： MELANCON CHARLES ,  HALL PAMELA ,  GREENBERG JACOB ,  OGASAWARA YASUSHI ,  ROGELJ SNEZNA

IPC: A61K31/03

CPC classification number: A61K31/192 ,  A61K31/122

Abstract: In one aspect, this disclosure describes a pharmaceutical composition that generally includes frankiamicin A and a pharmaceutically acceptable carrier. In another aspect, this disclosure describes a method of treating a subject having, or at risk of having, a condition caused by a microbial infection treatable with frankiamicin A. Generally, the method includes administering to the subject an amount of frankiamicin A effective to ameliorate at least one symptom or clinical sign of the condition.

Abstract translation: 在一个方面，本公开描述了一种通常包含法尼基霉素A和药学上可接受的载体的药物组合物。 另一方面，本公开内容描述了治疗患有或可能患有由可用弗农康宁A治疗的微生物感染引起的病症的受试者的方法。通常，所述方法包括向受试者施用有效改善弗米奇霉素A的量 至少一种症状或临床症状。

公开(公告)号：WO2016145279A8

公开(公告)日：2017-04-27

申请号：PCT/US2016021933

申请日：2016-03-11

Applicant: STC UNM ,  THE OFFICE OF INNOVATION COMMERCIALIZATION ,  HALL PAMELA R ,  DALY SETH MICHAEL ,  OBERLIES NICHOLAS HUNTER ,  RAJA HUZEFA A ,  FIGUEROA-SALDIVAR MARIO A ,  HORSWILL ALEXANDER ROBERT ,  KAVANAUGH JEFFREY SCOTT

Inventor： HALL PAMELA R ,  DALY SETH MICHAEL ,  OBERLIES NICHOLAS HUNTER ,  RAJA HUZEFA A ,  FIGUEROA-SALDIVAR MARIO A ,  HORSWILL ALEXANDER ROBERT ,  KAVANAUGH JEFFREY SCOTT

IPC: A61K31/122 ,  A61K31/7056 ,  A61P3/10 ,  A61P29/00 ,  A61P31/00

CPC classification number: A61K31/122

Abstract: This disclosure describes pharmaceutical compositions and methods that involve the use of a polyhydroxyanthraquinone to inhibit quorum sensing in a microbe. In some embodiments, the polyhydroxyanthraquinone may be effective to antagonize AgrA function in a microbe. In other embodiments, the polyhydroxyanthraquinone may be effective for prophylactic and/or therapeutic treatment of a skin and soft tissue infection (SSTI) of a subject by a microbe. In still other embodiments, the polyhydroxyanthraquinone may be effective to reduce, limit progression, ameliorate, or resolve, to any extent, a symptom or clinical sign of infection by a microbe.

Abstract translation: 本公开描述了涉及使用聚羟基蒽醌抑制微生物群体感应的药物组合物和方法。 在一些实施方案中，聚羟基蒽醌可有效拮抗微生物中的AgrA功能。 在其他实施方案中，聚羟基蒽醌可有效预防和/或治疗受试者的微生物的皮肤和软组织感染（SSTI）。 在其他实施方案中，聚羟基蒽醌可有效降低，限制进展，改善或解决任何程度的微生物感染的症状或临床征兆。